• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

0.8590 -0.0297 (-3.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 68,812
Open 0.9000
Bid (Size) 0.8305 (1,100)
Ask (Size) 0.8819 (2,000)
Prev. Close 0.8887
Today's Range 0.8400 - 0.9375
52wk Range 0.7560 - 8.250
Shares Outstanding 3,541,262
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ensysce Biosciences Expands Global Opioid Patent Portfolio
January 21, 2026
Via ACCESS Newswire
News headline image
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
January 08, 2026
Via ACCESS Newswire

Performance

YTD
-8.6%
-8.6%
1 Month
-22.6%
-22.6%
3 Month
-61.5%
-61.5%
6 Month
-61.7%
-61.7%
1 Year
-89.2%
-89.2%

More News

Read More
News headline image
Ensysce Biosciences Issues Annual Shareholder Letter
January 05, 2026
Via ACCESS Newswire
News headline image
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
December 09, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
December 02, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
November 20, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
June 04, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
November 17, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Reports Third Quarter 2025 Financial Results
November 14, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
October 13, 2025
Via Benzinga
News headline image
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
October 10, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
September 04, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
August 19, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Narrows Loss in Q2 ↗
August 13, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
August 13, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
July 31, 2025
Via Benzinga
News headline image
Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
July 31, 2025
Via ACCESS Newswire
News headline image
These stocks that are showing activity before the opening bell on Wednesday. ↗
July 23, 2025
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
July 23, 2025
Via Benzinga
News headline image
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
July 16, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
June 24, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
June 11, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
May 16, 2025
Via Benzinga
News headline image
Ensysce Biosciences Reports First Quarter 2025 Financial Results
May 13, 2025
Via ACCESS Newswire
News headline image
Ensysce Biosciences Bolsters Management Team with Regulatory Expert
May 12, 2025
Via ACCESS Newswire

Frequently Asked Questions

Is Ensysce Biosciences, Inc. - Common Stock publicly traded?
Yes, Ensysce Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Ensysce Biosciences, Inc. - Common Stock trade on?
Ensysce Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ensysce Biosciences, Inc. - Common Stock?
The ticker symbol for Ensysce Biosciences, Inc. - Common Stock is ENSC on the Nasdaq Stock Market
What is the current price of Ensysce Biosciences, Inc. - Common Stock?
The current price of Ensysce Biosciences, Inc. - Common Stock is 0.8590
When was Ensysce Biosciences, Inc. - Common Stock last traded?
The last trade of Ensysce Biosciences, Inc. - Common Stock was at 01/23/26 04:00 PM ET
What is the market capitalization of Ensysce Biosciences, Inc. - Common Stock?
The market capitalization of Ensysce Biosciences, Inc. - Common Stock is 3.04M
How many shares of Ensysce Biosciences, Inc. - Common Stock are outstanding?
Ensysce Biosciences, Inc. - Common Stock has 3M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap